Is transthyretin amyloid cardiomyopathy heading towards losing its rare disease classification?
Expert Rev Cardiovasc Ther
.
2025 Jan-Feb;23(1-2):1-4.
doi: 10.1080/14779072.2025.2463333.
Epub 2025 Feb 10.
Authors
Anouk Achten
1
,
Steven A Muller
2
3
4
,
Peter-Paul Zwetsloot
5
,
Michelle Michels
5
,
Peter van der Meer
6
,
Hans L A Nienhuis
7
,
Manon G van der Meer
2
4
,
Vanessa P M van Empel
1
,
Marish I F J Oerlemans
2
4
,
Christian Knackstedt
1
Affiliations
1
Department of Cardiology, Maastricht University, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.
2
Department of Cardiology, University Medical Centre, Utrecht, The Netherlands.
3
Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
4
Member of the European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart).
5
Cardiovascular Institute, Thoraxcenter, Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
6
Department of Cardiology, University Medical Centre, Groningen, The Netherlands.
7
Department of Internal Medicine, University Medical Centre, Groningen, The Netherlands.
PMID:
39928028
DOI:
10.1080/14779072.2025.2463333
No abstract available
Keywords:
ATTR; amyloid; amyloidosis; cardiomyopathy; genetic.
Publication types
Editorial